Figure S1. (A) Flinch count (median) for male mice following intraplantar formalin delivered at time 0. Mice received treatment: IP Vehicle, APAPp (200 mg/kg) 30 min prior to formalin. (B) presents the scattergram. for cumulative flinching count for Phase 1 and Phase 2 respectively. Analysis was performed non parametrically by Kruskal Wallis. Post hoc analysis for significant effects are shown (*: p<0.05; **:p<0.01).




Figure S2. (A) Flinch count for female mice following intraplantar formalin delivered at time 0. Mice received treatment: IP Vehicle, APAPp (300 mg/kg) 30 min prior to formalin. (B), (C) presents the scattergram. for cumulative flinching count for early phase and late phase respectively. Analysis was performed non parametrically by Kruskal Wallis. Post hoc analysis (Dunnett's T) for significant effects are shown (*: p<0.05; **:p<0.01).





Figure S3. Scattergram plots the median with 95% confidence intervals of the normalized flinch counts after treatment (APAP p: 100, 200 or 300 mg/kg in male mice or 300mg/kg in female mice) during phase 1 (left) and phase 2 (right). Flinch counts are normalized against the respective vehicle animals run in parallel with that APAPp dose. P values represent Kruskal-Wallis comparisons.



S3